• SELECT SITE CURRENCY
Select a currency for use throughout the site
The 43rd Meeting 2011 of the European Pancreatic Club - Post Conference Review and Analysis
GlobalData, June 2011, Pages: 27
The 43rd Meeting 2011 of the European Pancreatic Club – Post Conference Review and Analysis
GlobalData, the industry analysis specialist, has released its new conference alert, “The 43rd Meeting 2011 of the European Pancreatic Club – Post Conference Review and Analysis”. The conference alert is an essential source of information and analysis on the emerging therapies and new disease management techniques
The report provides complete coverage of conference. Its scope includes -
- Qualitative analysis of the studies and clinical trials presented at the conference and their impact on the key market dynamics and future treatment paradigm.
- Review of pre- and post-conference KOL/analyst comments
- Review of key industry trends and events which are likely to impact and change the dynamics of the concerned disease markets in the long run.
Reasons to buy
The report will serve to facilitate your decision making in the concerned therapy areas. It will allow you to -
- Develop business strategies by understanding the trends and developments that are driving or are expected to drive the market in the concerned disease areas.
- Explore M&A opportunities by identifying key products and market players.
- Develop market-entry and market expansion strategies.
- Identify key players best positioned to take advantage of the market opportunities.
- Make more informed business decisions from the insightful and in-depth analysis of the market and the factors influencing the same
1 Table of contents
1 Table of contents
2 The 43rd Meeting 2011 of the European Pancreatic Club - Key Conference Abstracts
2.1 Predictive Factors of Tumor Control in Patients with Pancreatic and Non-pancreatic Well Differentiated Digestive Endocrine Carcinomas Treated with Lanreotide
2.2 Antisense Inhibition of Microrna-21 and-221 in Tumor-Initiating Stem-Like Cells Modulates Biological Functions of Pancreatic Cancer Including Tumorigenesis, Metastasis, and Chemo resistance
2.3 Neoadjuvant/Preoperative Gemcitabine for Patients with Localized Pancreatic Cancers: a Meta-Analysis of Prospective Studies
2.4 Replicative-Stress Induced Midkine Expression is Linked to Chemoresistance in Pancreatic Cancer
2.5 The Accuracy of MDCT in Prediction of the Pancreatic Cancer Size
2.6 Gemcitabine Resistance in Pancreatic Cancer is Linked to Side-Population/Tumor Initiating Cells
2.7 Disrupting a Nuclear NFATc2 Stabilization Loop Confers Cancer Growth Suppression by Zoledronic Acid.
2.8 AT13387, a Novel HSP90 Inhibitor Induces Cytostatic Effects in Pancreatic Cancer Cell Lines
2.9 AT7519, a Novel CDK Inhibitor, Is Effective Against Gemcitabine Resistant Pancreatic Cancer Cell Lines
2.10 EGFR-independent Mechanism of Erlotinib in Pancreatic Ductal Adenocarcinoma Cells
2.11 Erythropoietin, Erythropoietin Receptor Expression and Signaling in Pancreatic Cancer
2.12 Characterization of the Anti-Pancreatic Tumor Cell Effect Induced by LBH589 and TSA and its Relation to HDAC Encoding Genes Expression
2.13 Development of Multiple Reaction Monitoring Techniques for the Quantification of Biomarkers of Pancreatic Cancer
2.14 In Vivo Diagnosis of Murine Pancreatic Intraepithelial Neoplasia and Early-Stage Pancreatic Cancer by Molecular Imaging of Cathepsin Activity
2.15 FOLFIRI Regimen as Second/Third-Line Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma Refractory to Gemcitabine and Platinum-Salts: A Retrospective Series of 70 Patients
2.16 Interference with Estrogen Receptor Signaling Inhibits Human Pancreatic Adenocarcinoma Growth
2.17 Discovery of New Serum Biomarkers for Pancreatic Cancer Diagnosis by MALDI-TOF Analysis
2.18 Tumour Origin of Adenocarcinomas in the Pancreatic Head – Impact on Survival and Prognostic Factors
2.19 Disseminated Tumor Cells in Pancreatic Cancer – An Independent Prognosticator of Disease Progression and Survival
2.20 Cystic Masses of the Pancreas: How Useful is Cyst Fluid Analysis in the Diagnosis?
2.21 Molecular Analysis of Pancreatic Cyst Fluid in Pancreatic Malignancy Diagnosis
2.22 Prognostic Profiling of 1071 Patients with Resected Pancreatic Cancer: A New Risk Stratification Results in Better Prediction of Outcome
2.23 Patterns of Recurrence after Curative Resection of Pancreatic Ductal Adenocarcinoma
2.24 Reclassification of Tumour Origin in Resected Periampullary Adenocarcinomas Reveals Under-recognized Diagnosis of Distal Bile Duct Cancer
2.25 Frequency and Endoscopic Ultrasound (EUS) Characteristics of Pancreatic Metastases: A Consecutive Study of a Large Series of Solid Pancreatic Masses
2.26 Pancreatic Cancer: Stromal S100A8/S100A9 Signaling
2.27 The Combination of Gemcitabine with the Dual PI3K/mTOR-Inhibitor NVP-BEZ235
2.28 Treatment of the Primary and Metastatic Solid-Pseudo papillary Tumors
2.29 Synergistic Interaction of Novel Lactate Dehydrogenase Inhibitors with Gemcitabine in Hypoxic Models of Pancreatic Cancer
2.30 PMP22 Genetic Alteration and Modulation of PMP22 Expression by NSC-631570 in Pancreatic Ductal Adenocarcinoma (PDAC)
2.31 GSK-3b Modulates an OncogenicTranscriptional Network in Pancreatic Cancer